Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older at the time of signing consent forms.
- People who are able to carry out basic daily activities, with limited or no restrictions due to their illness (confirmed using a standard medical performance scale called ECOG, scored 0 to 2).
- People who have been diagnosed with high-grade serous epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, confirmed through laboratory testing of tissue or cell samples.
- People whose cancer has come back or continued to grow and is considered "platinum-resistant" or "platinum-refractory" — meaning the cancer kept growing during platinum-based chemotherapy, or came back within 6 months of finishing it. A rising tumour marker (CA-125) alone does not count as meeting this criterion.
- People who have already received at least 2 prior treatment regimens, including their first-line (front-line) treatment.
- People who have read, understood, and signed the required consent and health information release forms.
Who may not be able to join:
- People who have another cancer (either past or current) where that cancer or its treatment could interfere with how this trial measures safety or effectiveness (confirm with trial site, as the wording of this criterion is complex).
- People who are not willing or not able to follow the study procedures, based on the assessment of the trial doctor or their designee.
- People who are not willing to have tissue biopsies taken before treatment starts, after an infusion, and if the disease gets worse — or whose tumour the treating doctor considers unsafe to biopsy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Linda Van Le, MD, UNC Lineberger Comprehensive Cancer Center
Phone: 919-445-4208
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity: NCI-CTCAE; Toxicity: Cytokine Release Syndrome (CRS); Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.